Dr. Amresh Raina, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 342
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
PA license MD427636 -
Cardiovascular Disease Physician
PA license MD427636
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Allegheny General Hospital Pittsburgh, PA
- West Penn Hospital Pittsburgh, PA
- Forbes Hospital Monroeville, PA
- Ahn Wexford Hospital Wexford, PA
- Canonsburg General Hospital Canonsburg, PA
Medical groups
- Allegheny Clinic (2,389 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 342
- Services billed
- 658
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 236 | 224 |
| Established patient office or other outpatient visit, 40-54 minutes | 99 | 68 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 85 | 33 |
| Critical care, first 30-74 minutes | 46 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 29 | 27 |
| Ultrasound of heart with probe in esophagus, with report | 21 | 21 |
| Established patient office or other outpatient visit, 30-39 minutes | 20 | 18 |
| Ultrasound of heart blood flow, valves and chambers | 20 | 20 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | 20 |
| Ultrasound of heart, follow-up | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Pittsburgh, PA | 246 |
| Bumetanide Other prescribers in Pittsburgh, PA | 208 |
| Entresto (sacubitril/valsartan) Other prescribers in Pittsburgh, PA | 154 |
| Carvedilol Other prescribers in Pittsburgh, PA | 150 |
| Digoxin Other prescribers in Pittsburgh, PA | 142 |
| Metoprolol Succinate Other prescribers in Pittsburgh, PA | 142 |
| Atorvastatin Calcium Other prescribers in Pittsburgh, PA | 126 |
| Lisinopril Other prescribers in Pittsburgh, PA | 110 |
| Eliquis (apixaban) Other prescribers in Pittsburgh, PA | 110 |
| Amlodipine Besylate Other prescribers in Pittsburgh, PA | 109 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $289 in total to this clinician.
| Abbott Laboratories | $141 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $98.99 |
| Sandoz Inc. | $29.96 |
| E.r. Squibb & Sons, L.l.c. | $19.34 |
| Food and Beverage | $190 |
|---|---|
| Education | $98.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Jun 5, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $98.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $173,934 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserv…
Merck Sharp & Dohme LLC - A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Ma…
Janssen Research & Development, LLC - BAY 632521, RiOciguAt UseRs Registry The ROAR registry
Bayer HealthCare Pharmaceuticals Inc. - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186 - A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate th…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.